Key result
Vaccination of maternally positive piglets at 2 and 3 weeks of age with Ingelvac PRRSFLEX EU significantly reduced mean lung lesion scores compared to non-vaccinated controls following a heterologous PRRSv challenge.
Why the study?
Does vaccination with Ingelvac PRRSFLEX EU induce immune response and protect piglets against heterologous PRRSv challenge in the presence of maternal immunity?
RCT (n=89)
Selected to minimize litter effect
No
Does vaccination with Ingelvac PRRSFLEX EU induce immune response and protect piglets against heterologous PRRSv challenge in the presence of maternal immunity?
Absolute Event Rate: 4.9% vs 10.4%
p-value: p=0.0125
Vaccination of piglets at 2 or 3 weeks of age with a modified live PRRSv vaccine overcomes maternal antibody interference and provides protection against heterologous viral challenge.
Supports vaccinating maternally immune piglets at 2-3 weeks; extends experimental data but leaves open field translation.
In this study, we analyzed PRRS virus (PRRSv) specific lymphocyte function in piglets vaccinated with Ingelvac PRRSFLEX EU® at two and three weeks of age in the presence of homologous maternal immunity. Complete analysis of maternal immunity to PRRSv was evaluated postpartum, as well as passive transfer of antibodies and T cells to the piglet through colostrum intake and before and after challenge with a heterologous PRRSv at ten weeks of age. Maternal-derived antibodies were detected in piglets but declined quickly after weaning. However, vaccinated animals restored PRRSv-specific antibody levels by anamnestic response to vaccination. Cell analysis in colostrum and milk revealed presence of PRRSv-specific immune cells at suckling with higher concentrations found in colostrum than in milk. In addition, colostrum and milk contained PRRSv-specific IgA and IgG that may contribute to protection of newborn piglets. Despite the presence of PRRSv-specific Peripheral Blood Mononuclear cells (PBMCs) in colostrum and milk, no PRRSv-specific cells could be detected from blood of the piglets at one or two weeks of life. Nevertheless, cellular immunity was detectable in pre-challenged piglets up to 7 weeks after vaccination while the non-vaccinated control group showed no interferon (IFN) γ response to PRRSv stimulation. After challenge, all piglets developed a PRRSv-specific IFNγ-response, which was more robust at significantly higher levels in vaccinated animals compared to the primary response to PRRSv in non-vaccinated animals. Cytokine analysis in the lung lumen showed a reduction of pro-inflammatory responses to PRRSv challenge in vaccinated animals, especially reduced interferon (IFN) α levels. In conclusion, vaccination of maternally positive piglets at 2 and 3 weeks of age with Ingelvac PRRSFLEX EU induced a humoral and cellular immune response to PRRSv and provided protection against virulent, heterologous PRRSv challenge.
No takes yet. Share an insight, caveat, or question.
Kraft et al. (2019) conducted an RCT in Porcine reproductive and respiratory syndrome virus (PRRSv) infection (n=89). Ingelvac PRRSFLEX EU vs. Placebo mock vaccination was evaluated on Total mean lung lesion score at 10 days post challenge (p=0.0125). Vaccination of maternally positive piglets at 2 and 3 weeks of age with Ingelvac PRRSFLEX EU significantly reduced mean lung lesion scores compared to non-vaccinated controls following a heterologous PRRSv challenge.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: